Hydroxyethyl-starch solutions for infusion recommended for suspension from the market
25. Februar 2022 – On 11 February 2022, EMA’s safety committee, PRAC, recommended that the marketing authorisations for hydroxyethyl-starch (HES) solutions for infusion should be suspended across the European Union. These products were authorised as an addition to other treatments for plasma volume replacement following acute (sudden) blood loss.
For more information, see here.